TRANSLATE

The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

ZUMA-3 trial update of brexucabtagene autoleucel in adult patients with R/R B-ALL

Featured:

Bijal ShahBijal Shah

Jul 25, 2022

Learning objective: After reading this article, learners will be able to cite a new clinical development in B-cell ALL.


During the 2022 ASCO Annual Meeting, the ALL Hub spoke with Bijal D. Shah, Moffit Cancer Center, Tampa, US. We asked for a ZUMA-3 trial update of brexucabtagene autoleucel in adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL).

ZUMA-3 trial update of brexucabtagene autoleucel in adult patients with R/R B-ALL

Shah shares data from the 2-year follow-up of the ZUMA-3 trial, discussing the long-term impact of allogeneic stem cell transplants. Shah outlines promising findings on overall survival for different patient groups and highlights a lack of trend in toxicity data.